EPS for Curis, Inc. (CRIS) Expected At $-0.41

July 11, 2018 - By Duane Lopez

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment decreased to 0.86 in Q1 2018. Its down 0.73, from 1.59 in 2017Q4. It dived, as 10 investors sold Curis, Inc. shares while 25 reduced holdings. 14 funds opened positions while 16 raised stakes. 62.11 million shares or 17.79% less from 75.55 million shares in 2017Q4 were reported.
Aqr Capital Lc, a Connecticut-based fund reported 468,984 shares. State Bank Of Ny Mellon Corporation, a New York-based fund reported 380,559 shares. 12,996 were accumulated by American Century. Janney Montgomery Scott accumulated 86,600 shares or 0% of the stock. Strs Ohio accumulated 0% or 48,500 shares. Silvercrest Asset Management Grp Ltd Llc stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Grp One Trading Lp has 12,167 shares. Proshare Limited Liability Corp has 92,722 shares for 0% of their portfolio. Weiss Multi has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Prelude Limited Com holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 2,768 shares. Mackenzie Financial has invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). Meridian Counsel holds 10,000 shares or 0% of its portfolio. Goldman Sachs Gru reported 0% in Curis, Inc. (NASDAQ:CRIS). Manufacturers Life Insur The has 5,362 shares for 0% of their portfolio. State Of Wisconsin Inv Board has 0% invested in Curis, Inc. (NASDAQ:CRIS).

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.41 EPS on August, 2.They anticipate $0.09 EPS change or 18.00 % from last quarter’s $-0.5 EPS. After having $-0.35 EPS previously, Curis, Inc.’s analysts see 17.14 % EPS growth. The stock increased 3.37% or $0.06 during the last trading session, reaching $1.84. About 143,273 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 73.52% since July 12, 2017 and is downtrending. It has underperformed by 86.09% the S&P500.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis had 2 analyst reports since May 7, 2018 according to SRatingsIntel. SunTrust maintained it with “Buy” rating and $1800 target in Thursday, May 31 report. The rating was maintained by Robert W. Baird with “Outperform” on Monday, May 7.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $60.95 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

More recent Curis, Inc. (NASDAQ:CRIS) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Titan’s Parkinson’s Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32 …” on July 03, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with publication date: June 29, 2018 was also an interesting one.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.